Literature DB >> 10087226

Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.

S V Narayan1, S Mukherjee, F Jia, Z Li, C Wang, L Foresman, C McCormick-Davis, E B Stephens, S V Joag, O Narayan.   

Abstract

A chimeric simian-human immunodeficiency virus (SHIV-4) containing the tat, rev, vpu, and env genes of HIV type 1 (HIV-1) in a genetic background of SIVmac239 was used to develop an animal model in which a primate lentivirus expressing the HIV-1 envelope glycoprotein caused acquired immune deficiency syndrome (AIDS) in macaques. An SHIV-infected pig-tailed macaque that died from AIDS at 24 weeks postinoculation experienced two waves of viremia: one extending from weeks 2-8 and the second extending from week 18 until death. Virus (SHIVKU-1) isolated during the first wave was neutralized by antibodies appearing at the end of the first viremic phase, but the virus (SHIVKU-1b) isolated during the second viremic phase was not neutralized by these antibodies. Inoculation of SHIVKU-1b into 4 pig-tailed macaques resulted in severe CD4(+) T cell loss by 2 weeks postinoculation, and all 4 macaques died from AIDS at 23-34 weeks postinoculation. Because this virus had a neutralization-resistant phenotype, we sequenced the env gene and compared these sequences with those of the env gene of SHIVKU-1 and parental SHIV-4. With reference to SHIV-4, SHIVKU-1b had 18 and 6 consensus amino acid substitutions in the gp120 and gp41 regions of Env, respectively. These compared with 10 and 3 amino acid substitutions in the gp120 and gp41 regions of SHIVKU-1. Our data suggested that SHIVKU-1 and SHIVKU-1b probably evolved from a common ancestor but that SHIVKU-1b did not evolve from SHIVKU-1. A chimeric virus, SHIVKU-1bMC17, constructed with the consensus env from the SHIVKU-1b on a background of SHIV-4, confirmed that amino acid substitutions in Env were responsible for the neutralization-resistant phenotype. These results are consistent with the hypothesis that neutralizing antibodies induced by SHIVKU-1 in pig-tailed macaque resulted in the selection of a neutralization-resistant virus that was responsible for the second wave of viremia. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087226     DOI: 10.1006/viro.1999.9605

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.

Authors:  Yasuyuki Eda; Toshio Murakami; Yasushi Ami; Tadashi Nakasone; Mari Takizawa; Kenji Someya; Masahiko Kaizu; Yasuyuki Izumi; Naoto Yoshino; Shuzo Matsushita; Hirofumi Higuchi; Hajime Matsui; Katsuaki Shinohara; Hiroaki Takeuchi; Yoshio Koyanagi; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.

Authors:  Regina Hofmann-Lehmann; Josef Vlasak; Agnès-Laurence Chenine; Pei-Lin Li; Timothy W Baba; David C Montefiori; Harold M McClure; Daniel C Anderson; Ruth M Ruprecht
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation.

Authors:  Amjad Hussain; Clement Wesley; Mohammad Khalid; Ashutosh Chaudhry; Shahid Jameel
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.

Authors:  Jason A LaBonte; Navid Madani; Joseph Sodroski
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.

Authors:  Laryssa Howe; Caroline Leroux; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.